Assessment of stability, toxicity and immunogenicity of new polymeric nanoreactors for use in enzyme replacement therapy of MNGIE

Journal of Controlled Release

Volumn 137, Issue 3, 2009, Pages 246-254

  De Vocht, Caroline ^a,b   Ranquin, An ^a,b   Willaert, Ronnie ^a,b   Van Ginderachter, Jo A ^a,b   Vanhaecke, Tamara ^a   Rogiers, Vera ^a   Versées, Wim ^a,b   Van Gelder, Patrick ^a,b   Steyaert, Jan ^a,b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Drug delivery; Enzyme replacement therapy; MNGIE; Nanoreactor; Polymeric nanoparticles

Indexed keywords

BLOOD SERUM; ENZYME REPLACEMENT THERAPY; EX-VIVO; GENETIC DISORDERS; HEPATOCYTES; HUMAN ENZYMES; IMMUNOGENICITY; IN-VIVO; INFLAMMATORY RESPONSE; METABOLIC ENZYMES; MNGIE; NATIVE ENZYMES; POLYMERIC NANOPARTICLES; SUBSTRATE CONCENTRATIONS; THERAPEUTIC ENZYME; THYMIDINE PHOSPHORYLASE; TOXIC SUBSTRATES;

DRUG DELIVERY; ENZYMES; FUNCTIONAL POLYMERS; LEAD; NANOPARTICLES; NANOREACTORS; PHOSPHORYLATION; SILICONES; SUBSTRATES;

POLYMERS;

COPOLYMER; DIMETICONE; NANOPARTICLE; NUCLEOSIDE; POLY(2 METHYLOXAZOL); PORIN; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOREACTOR; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME REPLACEMENT; ENZYME STABILITY; EX VIVO STUDY; IMMUNOGENICITY; IN VIVO STUDY; INCUBATION TIME; LIVER CELL; MACROPHAGE; MALE; MNGIE SYNDROME; MOUSE; NANOENCAPSULATION; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; RAT; TEMPERATURE MEASUREMENT;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; CELL SURVIVAL; CELLS, CULTURED; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; HEPATOCYTES; L-LACTATE DEHYDROGENASE; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; OXAZOLES; PARTICLE SIZE; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VIRUS; THYMIDINE PHOSPHORYLASE;

EID: 67649126215     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.03.020     Document Type: Article

References (64)

1. Guggenbuhl P., Grosbois B., and Chales G. Gaucher disease. Joint Bone Spine 75 2 (2008) 116-124
2. Amalfitano A., Bengur A.R., Morse R.P., Majure J.M., Case L.E., Veerling D.L., Mackey J., Kishnani P., Smith W., McVie-Wylie A., Sullivan J.A., Hoganson G.E., Phillips 3rd J.A., Schaefer G.B., Charrow J., Ware R.E., Bossen E.H., and Chen Y.T. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet. Med. 3 2 (2001) 132-138
3. Brady R.O., and Schiffmann R. Clinical features of and recent advances in therapy for Fabry disease. Jama 284 21 (2000) 2771-2775
4. Nishino I., Spinazzola A., and Hirano M. MNGIE: from nuclear DNA to mitochondrial DNA. Neuromuscul. Disord. 11 1 (2001) 7-10
5. Spinazzola A., Marti R., Nishino I., Andreu A.L., Naini A., Tadesse S., Pela I., Zammarchi E., Donati M.A., Oliver J.A., and Hirano M. Altered thymidine metabolism due to defects of thymidine phosphorylase. J. Biol. Chem. 277 6 (2002) 4128-4133
6. Nishino I., Spinazzola A., and Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 283 5402 (1999) 689-692
7. Valentino M.L., Marti R., Tadesse S., Lopez L.C., Manes J.L., Lyzak J., Hahn A., Carelli V., and Hirano M. Thymidine and deoxyuridine accumulate in tissues of patients with Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE). FEBS Lett. 581 18 (2007) 3410-3414
8. Lara M.C., Weiss B., Illa I., Madoz P., Massuet L., Andreu A.L., Valentino M.L., Anikster Y., Hirano M., and Marti R. Infusion of platelets transiently reduces nucleoside overload in MNGIE. Neurology 67 8 (2006) 1461-1463
9. Hirano M., Marti R., Casali C., Tadesse S., Uldrick T., Fine B., Escolar D.M., Valentino M.L., Nishino I., Hesdorffer C., Schwartz J., Hawks R.G., Martone D.L., Cairo M.S., DiMauro S., Stanzani M., Garvin Jr. J.H., and Savage D.G. Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. Neurology 67 8 (2006) 1458-1460
10. Chinnery P.F., and Vissing J. Treating MNGIE: is reducing blood nucleosides the first cure for a mitochondrial disorder?. Neurology 67 8 (2006) 1330-1332
11. Burrow T.A., Hopkin R.J., Leslie N.D., Tinkle B.T., and Grabowski G.A. Enzyme reconstitution/replacement therapy for lysosomal storage diseases. Curr. Opin. Pediatr. 19 6 (2007) 628-635
12. Wilcox W.R., Banikazemi M., Guffon N., Waldek S., Lee P., Linthorst G.E., Desnick R.J., and Germain D.P. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 75 1 (2004) 65-74
13. Barton N.W., Brady R.O., Dambrosia J.M., Di Bisceglie A.M., Doppelt S.H., Hill S.C., Mankin H.J., Murray G.J., Parker R.I., and Argoff C.E. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 324 21 (1991) 1464-1470
14. Achord D.T., Brot F.E., Bell C.E., and Sly W.S. Human beta-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell 15 1 (1978) 269-278
15. Harris J.M., and Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2 3 (2003) 214-221
16. Hershfield M.S. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin. Immunol. Immunopathol. 76 3 Pt 2 (1995) S228-232
17. Gaberc-Porekar V., Zore I., Podobnik B., and Menart V. Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr. Opin. Drug Discov. Dev. 11 2 (2008) 242-250
18. Allen T.M., and Cullis P.R. Drug delivery systems: entering the mainstream. Science 303 5665 (2004) 1818-1822
19. Walde P., and Ichikawa S. Enzymes inside lipid vesicles: preparation, reactivity and applications. Biomol. Eng. 18 4 (2001) 143-177
20. Yamauchi M., Tsutsumi K., Abe M., Uosaki Y., Nakakura M., and Aoki N. Release of drugs from liposomes varies with particle size. Biol. Pharm. Bull. 30 5 (2007) 963-966
21. Gabizon A., Chisin R., Amselem S., Druckmann S., Cohen R., Goren D., Fromer I., Peretz T., Sulkes A., and Barenholz Y. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br. J. Cancer 64 6 (1991) 1125-1132
22. Klibanov A.L., Maruyama K., Torchilin V.P., and Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268 1 (1990) 235-237
23. Laverman P., Carstens M.G., Boerman O.C., Dams E.T., Oyen W.J., van Rooijen N., Corstens F.H., and Storm G. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J. Pharmacol. Exp. Ther. 298 2 (2001) 607-612
24. Discher D.E. Emerging applications of polymersomes in delivery: From molecular dynamics to shrinkage of tumors. Prog. Polym. Sci. 32 (2007) 838-857
25. Discher D.E., and Eisenberg A. Polymer vesicles. Science 297 5583 (2002) 967-973
26. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., and Langer R. Biodegradable long-circulating polymeric nanospheres. Science 263 5153 (1994) 1600-1603
27. Panyam J., and Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55 3 (2003) 329-347
28. Genta I., Perugini P., Pavanetto F., Maculotti K., Modena T., Casado B., Lupi A., Iadarola P., and Conti B. Enzyme loaded biodegradable microspheres in vitro ex vivo evaluation. J. Control. Release 77 3 (2001) 287-295
29. Nardin C., Hirt T., Leukel J., and Meier W. Polymerized ABA triblock copolymer vesicles. Langmuir 16 3 (2000) 1035-1041
30. Nardin C., and Meier W. Hybrid materials from amphiphilic block copolymers and membrane proteins. J. Biotechnol. 90 1 (2002) 17-26
31. Nardin C., Widmer J., Winterhalter M., and Meier W. Amphiphilic block copolymer nanocontainers as bioreactors. Eur. Phys. J. E 4 (2001) 403-410
32. Ye J., and Van Den Berg B. Crystal structure of the bacterial nucleoside transporter Tsx. EMBO J. 23 16 (2004) 3187-3195 Electronic publication 2004 Jul 3122
33. Woodle M.C. Controlling liposome blood clearance by surface-grafted polymers. Adv. Drug Deliv. Rev. 32 1-2 (1998) 139-152
34. Zalipsky S., Hansen C.B., Oaks J.M., and Allen T.M. Evaluation of blood clearance rates and biodistribution of poly(2-oxazoline)-grafted liposomes. J. Pharm. Sci. 85 2 (1996) 133-137
35. Ranquin A., Versees W., Meier W., Steyaert J., and Van Gelder P. Therapeutic nanoreactors: combining chemistry and biology in a novel triblock copolymer drug delivery system. Nano Lett. 5 11 (2005) 2220-2224
36. Broz P., Ben-Haim N., Grzelakowski M., Marsch S., Meier W., and Hunziker P. Inhibition of macrophage phagocytotic activity by a receptor-targeted polymer vesicle-based drug delivery formulation of pravastatin. J. Cardiovasc. Pharmacol. 51 3 (2008) 246-252
37. Vamvakaki V., and Chaniotakis N.A. Pesticide detection with a liposome-based nano-biosensor. Biosens. Bioelectron. 22 12 (2007) 2848-2853
38. Gitsov I., Hamzik J., Ryan J., Simonyan A., Nakas J.P., Omori S., Krastanov A., Cohen T., and Tanenbaum S.W. Enzymatic nanoreactors for environmentally benign biotransformations. 1. Formation and catalytic activity of supramolecular complexes of laccase and linear-dendritic block copolymers. Biomacromolecules 9 3 (2008) 804-811
39. Broz P., Benito S.M., Saw C., Burger P., Heider H., Pfisterer M., Marsch S., Meier W., and Hunziker P. Cell targeting by a generic receptor-targeted polymer nanocontainer platform. J. Control. Release 102 2 (2005) 475-488
40. Broz P., Driamov S., Ziegler J., Ben-Haim N., Marsch S., Meier W., and Hunziker P. Toward intelligent nanosize bioreactors: a pH-switchable, channel-equipped, functional polymer nanocontainer. Nano Lett. 6 10 (2006) 2349-2353
41. Ben-Haim N., Broz P., Marsch S., Meier W., and Hunziker P. Cell-specific integration of artificial organelles based on functionalized polymer vesicles. Nano Lett. 8 5 (2008) 1368-1373
42. Prilipov A., Phale P.S., Van Gelder P., Rosenbusch J.P., and Koebnik R. Coupling site-directed mutagenesis with high-level expression: large scale production of mutant porins from E. coli. FEMS Microbiol. Lett. 163 1 (1998) 65-72
43. Graff A., Sauer M., Van Gelder P., and Meier W. Virus-assisted loading of polymer nanocontainer. Proc. Natl. Acad. Sci. U. S. A. 99 8 (2002) 5064-5068 Electronic publication 2002 Mar 5026
44. Dunn D.B., and Hill S.C. CRC Handbook of Biochemistry (1970), CRC Press, Florida G58
45. Huysmans G., Ranquin A., Wyns L., Steyaert J., and Van Gelder P. Encapsulation of therapeutic nucleoside hydrolase in functionalised nanocapsules. J. Control. Release 102 1 (2005) 171-179
46. Henkens T., Papeleu P., Elaut G., Vinken M., Rogiers V., and Vanhaecke T. Trichostatin A, a critical factor in maintaining the functional differentiation of primary cultured rat hepatocytes. Toxicol. Appl. Pharmacol. 218 1 (2007) 64-71
47. Korzeniewski C., and Callewaert D.M. An enzyme-release assay for natural cytotoxicity. J. Immunol. Methods 64 3 (1983) 313-320
48. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 1-2 (1983) 55-63
49. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., and Tannenbaum S.R. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem. 126 1 (1982) 131-138
50. Comiskey S.J., and Heath T.D. Serum-induced leakage of negatively charged liposomes at nanomolar lipid concentrations. Biochemistry 29 15 (1990) 3626-3631
51. Ishida T., Harashima H., and Kiwada H. Liposome clearance. Biosci. Rep. 22 2 (2002) 197-224
52. Brandon E.F., Raap C.D., Meijerman I., Beijnen J.H., and Schellens J.H. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol. Appl. Pharmacol. 189 3 (2003) 233-246
53. Papeleu P., Vanhaecke T., Henkens T., Elaut G., Vinken M., Snykers S., and Rogiers V. Isolation of rat hepatocytes. Methods Mol. Biol. 320 (2006) 229-237
54. Nagata S., and Golstein P. The Fas death factor. Science 267 5203 (1995) 1449-1456
55. Ito K., Kiyosawa N., Kumagai K., Manabe S., Matsunuma N., and Yamoto T. Molecular mechanism investigation of cycloheximide-induced hepatocyte apoptosis in rat livers by morphological and microarray analysis. Toxicology 219 1-3 (2006) 175-186
56. Worle-Knirsch J.M., Pulskamp K., and Krug H.F. Oops they did it again! Carbon nanotubes hoax scientists in viability assays. Nano Lett. 6 6 (2006) 1261-1268
57. Laaksonen T., Santos H., Vihola H., Salonen J., Riikonen J., Heikkila T., Peltonen L., Kumar N., Murzin D.Y., Lehto V.P., and Hirvonen J. Failure of MTT as a toxicity testing agent for mesoporous silicon microparticles. Chem. Res. Toxicol. 20 12 (2007) 1913-1918
58. Dobrovolskaia M.A., Aggarwal P., Hall J.B., and McNeil S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5 4 (2008) 487-495
59. Daniels A.U., Barnes F.H., Charlebois S.J., and Smith R.A. Macrophage cytokine response to particles and lipopolysaccharide in vitro. J. Biomed. Mater Res. 49 4 (2000) 469-478
60. Catelas I., Petit A., Marchand R., Zukor D.J., Yahia L., and Huk O.L. Cytotoxicity and macrophage cytokine release induced by ceramic and polyethylene particles in vitro. J. Bone Jt. Surg. Br. 81 3 (1999) 516-521
61. Murray H.W., Spitalny G.L., and Nathan C.F. Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma. J. Immunol. 134 3 (1985) 1619-1622
62. Prabhu A., Shelburne C.E., and Gibbons D.F. Cellular proliferation and cytokine responses of murine macrophage cell line J774A.1 to polymethylmethacrylate and cobalt-chrome alloy particles. J. Biomed. Mater Res. 42 4 (1998) 655-663
63. Tripathi P., Tripathi P., Kashyap L., and Singh V. The role of nitric oxide in inflammatory reactions. FEMS Immuno.l Med. Microbiol. 51 3 (2007) 443-452
64. Pata V., and Dan N. The effect of chain length on protein solubilization in polymer-based vesicles (polymersomes). Biophys. J. 85 4 (2003) 2111-2118